Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market Is Growing With a Good Pace: Statistics Report by Credence Research

The key players in the global Neoantigen-Based Personalized Cancer Therapeutic Vaccines market in terms of value include NEC Corporation, BrightPath therapeutics, CUREVAC N.V., Geneos Therapeutics, Vaccibody, Transgene, Neon Therapeutic, Genocea Biosciences, Moderna, Advaxis, AstraZeneca, Gritstone Oncology, Inc., Incyte Corporation, Hangzhou Neoantigen Therapeutics and Frame Pharmaceuticals.

The Neoantigen-Based Personalized Cancer Therapeutic Vaccines market has grown primarily due to major market drivers such as rising cancer prevalence, increased adoption of personalized medicine to tailor patient treatment on an individual level, and significant external funding for research and development. However, rapid technological advancements and infrastructure developments in the healthcare sector are driving the growth of the Neoantigen-Based Personalized Cancer Therapeutic Vaccines market. Furthermore, increasing investments by governing bodies and healthcare providers are expected to drive the growth of the neoantigen cancer vaccine market globally in the coming years. The increased market size is also expected as a result of rising awareness about the current unmet need for adjuvant therapies, as well as incremental healthcare spending around the world, which would expand the market size and allow vaccine manufacturers to penetrate further into the market. A better understanding of disease pathogenesis will also help to develop novel therapies for Neoantigen-based Personalized Cancer Therapeutic Vaccines which drives the growth of Neoantigen-Based Personalized Cancer Therapeutic Vaccines market.

In order to stimulate the body’s immune system, cancer vaccines use viruses, bacteria, or other infection-causing agents that have been weakened or killed. These vaccines are intended to function similarly, stimulating the immune system to identify, target, and eliminate cancer cells. As a result of their recognition of cancer cells as foreign, they prime the immune system to combat them. One way to use the immune system of the body to fight cancer is through cancer vaccines.Another class of alluring antigens for therapeutic cancer vaccines are neoantigens that result from cancer-specific mutations. The risk of autoimmunity as well as the potential induction of central and peripheral tolerance are reduced by vaccination against the tumor-specific neoantigens. Recent preclinical and early-phase clinical studies have demonstrated a significant therapeutic potential for neoantigen-based cancer vaccines.

Browse Full Report with ToC:

Neoantigens, another name for tumor-specific antigens, are not found in normal cells and are produced as a result of random somatic mutations in tumour cells. Neoantigens could be recognised as non-self by the host immune system in contrast to those non-mutated self-antigens, making them appealing targets for immunotherapies that may have improved specificity, efficacy, and safety.

Nucleic acid, dendritic cell (DC)-based, tumour cell, and synthetic long peptide (SLP) vaccines are the main types of tumour vaccines that target neoantigens. Immune checkpoint inhibition therapy, radiotherapy, and chemotherapy may be combined to produce better therapeutic results. Several clinical trials have currently shown the safety and effectiveness of these vaccines. Because the majority of neoantigens are derived from distinctive mutations in each tumour genome, neoantigen-related immunotherapy is a truly personalised treatment. Therefore, the first step in creating such customised vaccines is the identification of patient-specific immunogenic neoantigens.

The global Neoantigen-Based Personalized Cancer Therapeutic Vaccines market is segmented into Drugs by the Route of Administration, Molecule Type, and Geography. Based on Drugs by the Route of Administration the market is categorized into Oral, Parenteral, Intravenous, Subcutaneous, Topical and Molecule Type. On the basis of molecule type, the market is segmented into Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy and Product Type. Based on geography, the market is segmented as North America, Europe, Asia Pacific, Latin America and the Middle East, and Africa.

Report Segmentation

Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market – By Drugs by the Route of Administration


Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market – By Molecule Route of Administration

Monoclonal Antibody
Small molecule
Gene therapy

Why to Buy This Report-

The report provides a qualitative as well as quantitative analysis of the global Neoantigen-Based Personalized Cancer Therapeutic Vaccines market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2016-to 2020, base year- 2021, and forecast period 2022-2028.
The report contains information related to the competitive landscape like how the key players in the market are operating at a global, regional, and country-level
In-depth analysis of the global market segmentation on the basis of Clinical causes, Type, Distribution Channel, and End user.
Research and development investments by government as well as major players.
The global Neoantigen-Based Personalized Cancer Therapeutic Vaccines market report also includes the analysis of the market at a global, regional, and country-level along with key market trends, major players analysis, market growth strategies, and key application areas.

Browse Full Report with ToC:

Related Reports:

Mobile Cancer Screening Devices Market

Solid Tumor Cancer Treatment Market

About Us

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, nonlegislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Media Contact
Company Name: Credence Research
Contact Person: Chris Smith
Email: Send Email
Phone: 18003618290
State: CA
Country: United States

Are you a market researcher?

Explore our research partnership options.


Find out what people like and dislike about your competitors, and compare it with your brand performance.

Competitor Analyzer

Generated by Feedzy
%d bloggers like this: